3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
23
Recruiting
12
Terminated
8
Active not recruiting
7
Unknown
5
Not yet recruiting
5
Withdrawn
1
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
1
Carcinoma
1
Interventions
pembrolizumab
19
Docetaxel
16
Magnetic Resonance Spectroscopy
14
Prednisone
13
Radiotherapy
11
bicalutamide
10
Leuprolide
10
Abiraterone Acetate
9
Radiosurgery
8
Cyclophosphamide
8
Biopsy
8
avelumab
7
atezolizumab
6
Specimen Handling
6
Interleukin-2
6
Gemcitabine
6
Bevacizumab
6
Androgen Antagonists
6
tremelimumab
5
gallium 68 PSMA-11
5
apalutamide
5
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Surveys and Questionnaires
5
Sunitinib
5
Paclitaxel
5
Metformin
5
Injections
5
Goserelin
5
Cisplatin
5
ALT-803
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Mitomycin
×
Genitourinary
×
Clear all
NCT04006691
2020-05-07
Retreatment
UroGen Pharma Ltd.
Phase 3
Withdrawn